---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-23-000072"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:10:00.114183+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics reports Q3 net loss of $41.5M; positive bexotegrast PSC interim data

## Summary
- Net loss of $41.5M vs $30.6M in prior-year quarter; R&D expense $32.3M, G&A $15.3M.
- Cash, cash equivalents and short-term investments of $523.6M, funding operations into H2 2026.
- Positive 12-week data from Phase 2a INTEGRIS-PSC trial; 160 mg dose showed statistically significant reduction in ELF and PRO-C3 vs placebo.
- DSMB recommended INTEGRIS-PSC continue without modification; 320 mg data expected Q1 2024.
- Appointed Minnie Kuo as Chief Development Officer and Mishima Gerhart as Chief Regulatory Officer.

## SEC filing metadata
- accession: 0001746473-23-000072
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647323000072/0001746473-23-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647323000072/plrx-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-23-000072
- JSON: https://secwatch.observer/filing/0001746473-23-000072.json
- Plain text: https://secwatch.observer/filing/0001746473-23-000072.txt

## Key facts
- Earnings Releases
  PLIANT THERAPEUTICS, INC. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000174647323000072/0001746473-23-000072-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.